IMPORTANT!

Clinical trials listed for ITP are a starting point for discussion with a health care professional. Be sure you understand all the implications of the proposed treatment and read the informed consent very carefully before enrolling in a clinical trial.

List of Clinical Trials

Phase 3 Clinical Study with Investigational Drug "fostamatinib"

Rigel Pharmaceuticals Inc. is conducting a Phase 3 clinical study with an investigational drug, fostamatinib, for the treatment of patients with persistent or chronic ITP. If you are 18 years of age or older, have had a diagnosis of ITP for at least 3 months and have previously received at least 1 typical regimen for the treatment of ITP you may be eligible. There are a number of clinical trial sites already open in the U.S., Canada and Europe.

More Information

Open-Label, Dose Escalation Study of PRTX-100 in Adults With Persistent/Chronic Immune Thrombocytopenia

Protalex, Inc., a clinical-stage biopharmaceutical company, is now enrolling patients in a Phase I/II open-label, dose-escalating study of PRTX-100 in adults with persistent/chronic ITP. Pre-clinical data indicate that PRTX-100 may have the potential to treat ITP by reducing the immune-mediated destruction of the platelets.

More Information